


**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims:**

1. (Currently Amended) A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof[[,]] and a hydrate thereof, and a solvate thereof:




wherein one of R<sup>1</sup> and R<sup>2</sup> represents hydrogen atom and the other represents the formula -X-A wherein A represents hydrogen atom or an acyl group, X represents oxygen atom or NH; one of R<sup>3</sup> and R<sup>4</sup> represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group, R<sup>5</sup> represents a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, a benzimidazolyl group which may be substituted, or a cycloalkyl group, Z represents a single bond or a C<sub>1</sub> to C<sub>4</sub> alkylene group ~~which may be substituted, or when Z is~~

~~substituted, said substituent may bind to R<sup>5</sup> to form a ring group, R<sup>6</sup> represents hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group, which may be substituted, or R<sup>6</sup> may bind to Z or R<sup>5</sup> to form a cyclic group, provided that~~ with the following provisos:

a compound represented by the following formula:



wherein each of A, Z, R<sup>5</sup> and R<sup>6</sup> has the same meaning as that defined above is excluded;

when R<sup>3</sup> is hydrogen atom, then Y is a sulfonyl group;

when R<sup>2</sup> is the formula -NH-A, R<sup>4</sup> is a hydrogen atom, and Y is a sulfonyl group, then R<sup>5</sup> is a phenyl group which is substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

2. (Currently Amended) The medicament according to claim 1, wherein R<sup>5</sup> is an aromatic ring a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

3. (Currently Amended) The medicament according to claim 1, wherein Z is a methylene group ~~which may be substituted, or when Z is substituted, said substituent may bind to R<sup>5</sup> to form a ring group.~~

4. (Previously Presented) The medicament according to claim 1, wherein Y is a sulfonyl group.

5. (Currently Amended) The medicament according to claim 1, wherein R<sup>1</sup> is a group represented by the formula ~~-O-A~~ -X-A wherein A represents a hydrogen atom or an acyl group, X represents an oxygen atom or NH, and R<sup>2</sup> is hydrogen atom.


6. (Previously Presented) The medicament according to claim 1, wherein the cancer therapy based on the mode of action of DNA injury is carried out by an administration of an anticancer agent and/or radiation.

7. (Original) The medicament according to claim 6, wherein the anticancer agent is selected from the group consisting of bleomycin, adriamycin, cisplatin, cyclophosphamide, mitomycinC, and a derivative thereof.

8. (Previously Presented) The medicament according to claim 1, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

9. (Currently Amended) A medicament for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) ~~and~~ or a pharmacologically acceptable salt thereof, ~~and~~ or a hydrate thereof ~~and~~ or a solvate thereof according to claim 1.

10. (Currently Amended) A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof according to claim 1, provided that the following ~~compounds are~~ compound is excluded:



11. (Currently Amended) A compound selected from the group consisting of the following compounds or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof[.]:

N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Dihydroxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Phenyl-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Dihydroxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,3-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,5-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;

5-Acetyloxy-N-benzyl naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,4-dichlorobenzyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-nitrobenzyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(tert-butyl)benzyl] naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(trifluoromethyl)benzyl] naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,3-dimethoxybenzyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-aminobenzyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-naphthylmethyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl] naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(pyridin-2-yl)methyl] naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(cyclohexylmethyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-phenyl naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2-phenethyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-phenethyl) naphthalene-2-sulfonamide;  
5-Acetyloxy-N-benzyl-N-methyl naphthalene-2-sulfonamide;  
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;



N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
5-Amino-N-benzyl-naphthalene-2-sulfonamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
~~6-Acetylamino-N-benzyl-naphthalene-1-sulfonamide;~~  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
~~6-Amino-N-benzyl-naphthalene-1-sulfonamide;~~  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
6-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

6-Amino-N-benzyl naphthalene-2-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzyl naphthalene-1-carboxamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

12. (Currently Amended) A medicament which comprises as an active ingredient a substance selected from the group consisting of a compound and a pharmacologically acceptable salt thereof[[,]] and a hydrate thereof, and a solvate thereof according to claim 10.

13. (Original) A medicament according to claim 12, which is used for enhancing an effect of a cancer therapy based on a mode of action of DNA injury.

14. (Currently Amended) The medicament according to claim 2, wherein Z is a methylene group ~~which may be substituted, or when Z is substituted, said substituent may bind to R<sup>5</sup> to form a ring group.~~

15. (Previously Presented) The medicament according to claim 2, wherein Y is a sulfonyl group.

16. (Currently Amended) The medicament according to claim 2, wherein R<sup>1</sup> is a group represented by the formula  $\text{-}\Theta\text{-A-}\underline{\text{-X-A}}$  wherein A represents hydrogen atom or an acyl group, X represents oxygen atom or NH, and R<sup>2</sup> is hydrogen atom.

17. (Previously Presented) The medicament according to claim 2, wherein R<sup>5</sup> is a substituted phenyl group.

18. (Currently Amended) The medicament according to claim 2, wherein the substance compound is selected from the group consisting of the following compounds[.]:

N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Dihydroxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methoxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(3-Methoxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Phenyl-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-[[ (4-methylphenyl)sulfonyl]oxy} naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-[[4-(4-methylphenyl)sulfonyl]oxy]naphthalene-1-sulfonamide;  
N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Dihydroxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Methoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,5-Dimethoxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3,4-Methylenedioxybenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;  
N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;  
5-Acetyloxy-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;  
5-Acetyloxy-N-phenyl-naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;  
5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;


N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;  
N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;  
N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;  
N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-naphthalene-2-sulfonamide;  
5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
5-Amino-N-benzyl-naphthalene-2-sulfonamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;  
~~6-Acetylamino-N-benzyl-naphthalene-1-sulfonamide;~~  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;  
~~6-Amino-N-benzyl-naphthalene-1-sulfonamide;~~  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Acetylamino-N-benzyl naphthalene-2-sulfonamide;  
6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
6-Amino-N-benzyl naphthalene-2-sulfonamide;  
6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;  
6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;  
5-Amino-N-benzyl naphthalene-1-carboxamide;  
5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide; and  
5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.


19. (Currently Amended) The medicament according to claim 2, wherein the ~~substance~~ compound is N-[4-(tert-butyl)benzyl]-5-[[4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide.

20. (Withdrawn-Currently Amended) A method for enhancing an effect of a cancer therapy based on a mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from the group consisting of a compound represented by the ~~following~~ general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof; according to claim 1, at a dose sufficient to enhance an effect of a cancer therapy.






wherein one of  $R^1$  and  $R^2$  represents hydrogen atom and the other represents the formula  $-X-A$  wherein A represents hydrogen atom or an acyl group, X represents oxygen atom or NH; one of  $R^3$  and  $R^4$  represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group,  $R^5$  represents a cyclic group which may be substituted, Z represents a single bond or a  $C_1$  to  $C_4$  alkylene group which may be substituted, or when Z is substituted, said substituent may bind to  $R^5$  to form a ring group,  $R^6$  represents hydrogen atom or a  $C_1$  to  $C_6$  alkyl group, which may be substituted, or  $R^6$  may bind to Z or  $R^5$  to form a cyclic group, provided that a compound represented by the following formula:




wherein each of A, Z,  $R^5$  and  $R^6$  has the same meaning as that defined above is excluded.


21. (Withdrawn-Currently Amended) The method according to claim 20, wherein  $R^5$  is an aromatic ring a phenyl group which may be substituted, a naphthyl group which

may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

22. (Withdrawn-Currently Amended): A method for reducing a side effect resulting from a cancer therapy based on the mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: according to claim 1,




~~wherein one of R<sup>1</sup> and R<sup>2</sup> represents hydrogen atom and the other represents the formula -X-A wherein A represents hydrogen atom or an acyl group, X represents oxygen atom or NH; one of R<sup>3</sup> and R<sup>4</sup> represents hydrogen atom and the other represents the following formula:~~



~~wherein Y represents a sulfonyl group or a carbonyl group, R<sup>5</sup> represents a cyclic group which may be substituted, Z represents a single bond or a C<sub>1</sub> to C<sub>4</sub> alkylene group which may be substituted, or when Z is substituted, said substituent may bind to R<sup>5</sup> to form a ring group, R<sup>6</sup> represents hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group, which may be~~

~~substituted, or R<sup>6</sup> may bind to Z or R<sup>5</sup> to form a cyclic group, provided that a compound represented by the following formula:~~



~~wherein each of A, Z, R<sup>5</sup> and R<sup>5</sup> has the same meaning as that defined above is excluded,~~  
at a dose sufficient to reduce the side effect of the cancer therapy.

23. (Withdrawn-Currently Amended) The method according to claim 22, wherein R<sup>5</sup> is ~~an aromatic ring~~ a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

24. (Currently Amended) The compound according to claim 10 or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof, wherein R<sup>5</sup> is ~~an aromatic ring~~ a phenyl group which may be substituted, a naphthyl group which may be substituted, a furyl group which may be substituted, a pyridyl group which may be substituted, or a benzimidazolyl group which may be substituted.

25. (Currently Amended) The compound according to claim 24 or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof, wherein A is a hydrogen atom, an acetyl group or a para-toluenesulfonyl group.